- Home
- SWKH vs INMB Comparison
SWKH vs INMB Comparison
Compare SWKH & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWKH
- INMB
- Stock Information
- Founded
- SWKH 1996
- INMB 2015
- Country
- SWKH United States
- INMB United States
- Employees
- SWKH N/A
- INMB N/A
- Industry
- SWKH Diversified Financial Services
- INMB Biotechnology: Pharmaceutical Preparations
- Sector
- SWKH Finance
- INMB Health Care
- Exchange
- SWKH Nasdaq
- INMB Nasdaq
- Market Cap
- SWKH 179.1M
- INMB 176.5M
- IPO Year
- SWKH 1999
- INMB 2019
- Fundamental
- Price
- SWKH $14.57
- INMB $6.38
- Analyst Decision
- SWKH Strong Buy
- INMB Strong Buy
- Analyst Count
- SWKH 1
- INMB 3
- Target Price
- SWKH $18.00
- INMB $24.33
- AVG Volume (30 Days)
- SWKH 16.8K
- INMB 660.2K
- Earning Date
- SWKH 08-14-2025
- INMB 07-31-2025
- Dividend Yield
- SWKH N/A
- INMB N/A
- EPS Growth
- SWKH 51.50
- INMB N/A
- EPS
- SWKH 1.41
- INMB N/A
- Revenue
- SWKH $34,906,000.00
- INMB $50,000.00
- Revenue This Year
- SWKH $52.93
- INMB $82.14
- Revenue Next Year
- SWKH N/A
- INMB $28,750.98
- P/E Ratio
- SWKH $10.07
- INMB N/A
- Revenue Growth
- SWKH 18.02
- INMB N/A
- 52 Week Low
- SWKH $12.00
- INMB $4.32
- 52 Week High
- SWKH $16.24
- INMB $10.50
- Technical
- Relative Strength Index (RSI)
- SWKH 60.29
- INMB 37.45
- Support Level
- SWKH $14.21
- INMB $6.68
- Resistance Level
- SWKH $14.89
- INMB $8.05
- Average True Range (ATR)
- SWKH 0.31
- INMB 0.62
- MACD
- SWKH 0.02
- INMB -0.10
- Stochastic Oscillator
- SWKH 79.80
- INMB 10.31
About SWKH SWK Holdings Corporation
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.